Hyderabad-based Bharat Biotech today said that the USFDA had earlier communicated that no new Emergency Use Authorisation (EUA) will be approved for covid vaccines, a day after its US partner Ocugen hit a major bump after FDA rejected EUA for Covaxin.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full Biologics License Applications (BLA) approval.
Bharat Biotech said biological license application process is the standard process for vaccines.
"No vaccine manufactured or developed in India has ever received Emergency Use Authorisation or full licensure form the USFDA,” it said in a statement.
So far, Covaxin has received EUA’s from 14 countries with more than 50 countries in process.
The company said that an additional clinical trial will be required to support the marketing application submission for Covaxin.
“With good herd immunity and significant percentage of the population vaccinated, the pandemic is reducing in the United States,” it added.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full Biologics License Applications (BLA) approval.
Bharat Biotech said biological license application process is the standard process for vaccines.
"No vaccine manufactured or developed in India has ever received Emergency Use Authorisation or full licensure form the USFDA,” it said in a statement.
So far, Covaxin has received EUA’s from 14 countries with more than 50 countries in process.
The company said that an additional clinical trial will be required to support the marketing application submission for Covaxin.
“With good herd immunity and significant percentage of the population vaccinated, the pandemic is reducing in the United States,” it added.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.